Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease.

abstract：OBJECTIVE:To evaluate the effect of cilostazol administration on warfarin pharmacokinetics and pharmacodynamics following a single 25 mg dose of warfarin. DESIGN:A randomised double-blind 2-period crossover with healthy volunteers receiving either 100 mg cilostazol twice daily for 13 days or matching placebo twice dai...

journal_title：Clinical pharmacokinetics

authors： Mallikaarjun S,Bramer SL

更新日期：1999-01-01 00:00:00

abstract：:To investigate the influence of the presence of oedema on the pharmacokinetics and pharmacodynamics of furosemide (frusemide) we selected 9 hospitalised patients (mean age 70.3 years, range 59 to 84 years) with severe congestive heart failure (NYHA III to IV) and an assessed amount of peripheral oedema of at least 5 k...

journal_title：Clinical pharmacokinetics

authors： Van Meyel JJ,Gerlag PG,Smits P,Russel FG,Tan Y,Van Ginneken CA,Gribnau FW

更新日期：1992-04-01 00:00:00

abstract：:The prevalence of HIV-associated neurocognitive disorder (HAND) is increasing despite the widespread use of combination antiretroviral therapy (ART). Initial reports suggest that the use of antiretrovirals with good central nervous system (CNS) penetration leads to better neurocognitive outcomes, but this has not yet ...

journal_title：Clinical pharmacokinetics

authors： Decloedt EH,Rosenkranz B,Maartens G,Joska J

更新日期：2015-06-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:The likelihood of detecting a therapeutic signal of an effective drug for schizophrenia is impeded by a high placebo effect and by high dropout of patients. Several unsuccessful trials of schizophrenia, at least partly due to highly variable placebo effects, have indicated the necessity for a ...

journal_title：Clinical pharmacokinetics

authors： Pilla Reddy V,Kozielska M,Johnson M,Suleiman AA,Vermeulen A,Liu J,de Greef R,Groothuis GM,Danhof M,Proost JH

更新日期：2012-04-01 00:00:00

abstract：:Population pharmacokinetic modelling is widely used within the field of clinical pharmacology as it helps to define the sources and correlates of pharmacokinetic variability in target patient populations and their impact upon drug disposition; and population pharmacokinetic modelling provides an estimation of drug pha...

journal_title：Clinical pharmacokinetics

authors： Sherwin CM,Kiang TK,Spigarelli MG,Ensom MH

更新日期：2012-09-01 00:00:00

abstract：BACKGROUND:Entecavir is an orally administered guanosine nucleoside analog with activity against hepatitis B virus (HBV) polymerase, which is approved for the treatment of chronic hepatitis B (CHB) infection in adults and children ≥2 years old (USA and EU). OBJECTIVE:To develop simplified entecavir dosing recommendati...

journal_title：Clinical pharmacokinetics

authors： Chan P,Mould DR,Tarif MA,Reynolds L,LaCreta F,Bertz R,Bifano M

更新日期：2016-12-01 00:00:00

abstract：:Hydroxymetabolites of the antidepressants nortriptyline and desipramine, like the parent drugs, inhibit neuronal uptake of noradrenaline (norepinephrine). In both plasma and cerebrospinal fluid (CSF), the concentrations of the 10-hydroxymetabolites of nortriptyline (10-OH-NT) are usually higher than those of the paren...

journal_title：Clinical pharmacokinetics

authors： Nordin C,Bertilsson L

更新日期：1995-01-01 00:00:00

abstract：:There are many pathological changes in patients with cystic fibrosis (CF) which can lead to alterations in drug disposition. Although, in patients with CF, the extent of drug absorption varies widely and the rate of absorption is slower, bioavailability is not altered. Plasma protein binding for the majority of drugs ...

journal_title：Clinical pharmacokinetics

authors： Rey E,Tréluyer JM,Pons G

更新日期：1998-10-01 00:00:00

abstract：OBJECTIVE:To assess the pharmacokinetic and pharmacodynamic behaviour of moxifloxacin in 15 consecutive elderly patients with acute exacerbation of chronic bronchitis (AECB) treated with the fixed oral moxifloxacin 400 mg/day regimen with the intent of verifying which degree of exposure may be ensured by this standard ...

journal_title：Clinical pharmacokinetics

authors： Pea F,Pavan F,Lugatti E,Dolcet F,Talmassons G,Screm MC,Furlanut M

更新日期：2006-01-01 00:00:00

abstract：OBJECTIVE:To obtain a pharmacokinetic profile of cyclosporin microemulsion formulation in patients with inflammatory bowel disease. PATIENTS AND PARTICIPANTS:58 consecutive patients (19 women and 39 men), aged 16 to 64 years (mean age 38 years), with a diagnosis of ulcerative colitis (29 patients) or Crohn's disease (...

journal_title：Clinical pharmacokinetics

authors： Latteri M,Angeloni G,Silveri NG,Manna R,Gasbarrini G,Navarra P

更新日期：2001-01-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Proprotein convertase subtilisin/kexin type 9 inhibition with monoclonal antibodies such as alirocumab significantly reduces low-density lipoprotein-cholesterol levels ± other lipid-lowering therapies. We aimed to develop and qualify a population pharmacokinetics (PopPK) model for alirocumab in...

journal_title：Clinical pharmacokinetics

authors： Djebli N,Martinez JM,Lohan L,Khier S,Brunet A,Hurbin F,Fabre D

更新日期：2017-10-01 00:00:00

abstract：:18 hypertensive patients with a glomerular filtration rate (GFR) between 3.8 and 113ml/min received guanfacine as single intravenous and multiple oral dose treatment. Mean plasma concentrations of guanfacine on the fifth day or oral treatment ranged from 6.5 to 8.6ng/ml in patients with normal renal function (GFR > 90...

journal_title：Clinical pharmacokinetics

authors： Kirch W,Köhler H,Braun W,von Gizycki C

更新日期：1980-09-01 00:00:00

abstract：:Dosage adjustments can be difficult and time-consuming, especially for the non-specialist. The objective of this investigation was to obtain shortcut formulae to calculate dosage adjustments for (i) a drug obeying linear pharmacokinetics (i.e. first order) and given orally, by a continuous infusion or by an intermitte...

journal_title：Clinical pharmacokinetics

authors： Belloto RJ Jr

更新日期：2009-01-01 00:00:00

abstract：:Creatine is a nonessential dietary component that, when supplemented in the diet, has shown physiological benefits in athletes, in animal-based models of disease and in patients with various muscle, neurological and neuromuscular disease. The clinical relevance of creatine supplementation is based primarily on its rol...

journal_title：Clinical pharmacokinetics

authors： Persky AM,Brazeau GA,Hochhaus G

更新日期：2003-01-01 00:00:00

abstract：BACKGROUND:People living with human immunodeficiency virus are ageing under combination antiretroviral treatments but data on drug exposure in serum and cerebrospinal fluid are limited. Dolutegravir is a widely used second-generation integrase strand transfer inhibitor: conflicting data suggest that neuropsychiatric si...

journal_title：Clinical pharmacokinetics

authors： Calcagno A,Moltó J,Borghetti A,Gervasoni C,Milesi M,Valle M,Avataneo V,Alcantarini C,Pla-Junca F,Trunfio M,D'Avolio A,Di Giambenedetto S,Cattaneo D,Di Perri G,Bonora S

更新日期：2021-01-01 00:00:00

abstract：:Many antiarrhythmic drugs introduced into the market during the past three decades have a chiral centre in their structure and are marketed as racemates. Most of these agents, including disopyramide, encainide, flecainide, mexiletine, propafenone and tocainide, belong to class I antiarrhythmics, whereas verapamil is a...

journal_title：Clinical pharmacokinetics

authors： Mehvar R,Brocks DR,Vakily M

更新日期：2002-01-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:Recent analysis revealed strong associations between prostate-specific antigen (PSA) dynamics and overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) and supported PSA dynamics as bridging surrogacy endpoints for clinical benefit from treatment with abiraterone ace...

journal_title：Clinical pharmacokinetics

authors： Xu XS,Ryan CJ,Stuyckens K,Smith MR,Saad F,Griffin TW,Park YC,Yu MK,De Porre P,Vermeulen A,Poggesi I,Nandy P

更新日期：2017-01-01 00:00:00

abstract：:Proprotein convertase subtilisin/kexin type 9 (PCSK9) increases plasma low-density lipoprotein cholesterol (LDL-C) by decreasing expression of the LDL receptor on hepatic cells. Evolocumab is a human monoclonal immunoglobulin G2 that binds specifically to human PCSK9 to reduce LDL-C. Evolocumab exhibits nonlinear kine...

journal_title：Clinical pharmacokinetics

authors： Kasichayanula S,Grover A,Emery MG,Gibbs MA,Somaratne R,Wasserman SM,Gibbs JP

更新日期：2018-07-01 00:00:00

abstract：:The classic approach to describe the pharmacological response to a drug is to analyse its concentration-effect relationship, using a variety of possible models such as maximum effect (Emax) models or sigmoid Emax models. The aim of this review is to discuss an alternative way of describing the pharmacological effect i...

journal_title：Clinical pharmacokinetics

authors： Alván G,Paintaud G,Wakelkamp M

更新日期：1999-05-01 00:00:00

abstract：:The pharmacokinetics of metoprolol have been studied in a group of patients with varying degrees of renal impairment and in healthy subjects after administration of 20 mg of metoprolol tartrate intravenously and 50 mg orally in a single dose and during steady-state conditions. There were no significant differences in ...

journal_title：Clinical pharmacokinetics

authors： Jordö L,Attman PO,Aurell M,Johansson L,Johnsson G,Regårdh CG

更新日期：1980-03-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:Bayesian forecasting (BF) methods for tobramycin dose individualisation has not seen widespread clinical adoption, despite being endorsed by clinical practice guidelines. Several freeware and commercial programmes using BF methods are available to support personalised dosing. This study evalua...

journal_title：Clinical pharmacokinetics

authors： Burgard M,Sandaradura I,van Hal SJ,Stacey S,Hennig S

更新日期：2018-08-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Vicriviroc is a small-molecule CCR5 antagonist currently in development for the treatment of HIV in patients on a regimen containing a ritonavir-boosted protease inhibitor. As renal disease and renal dysfunction are prevalent in the HIV-infected population, patients with varying degrees of rena...

journal_title：Clinical pharmacokinetics

authors： Kasserra C,Sansone-Parsons A,Keung A,Tetteh E,Assaf M,O'Mara E,Marbury T

更新日期：2010-06-01 00:00:00

abstract：:Platelets contribute significantly to arterial-occlusive thrombosis, one of the major causes of death and disease throughout the world. Consequently, inhibiting platelet function is a potentially important therapeutic goal. Among agents that inhibit platelet function, ticlopidine shows a wide spectrum of antiplatelet ...

journal_title：Clinical pharmacokinetics

authors： Desager JP

更新日期：1994-05-01 00:00:00

abstract：:The effects of anaesthesia and surgery on the pharmacokinetics of ketobemidone were studied in 12 patients. Plasma ketobemidone concentrations were assayed with a mass-fragmentographic method. The peroperative Vd(area) was 5.9 +/- 2.6L/kg and the terminal half-life was 3.9 +/- 1.7 h. In the postoperative period Vd(are...

journal_title：Clinical pharmacokinetics

authors： Tamsen A,Bondesson U,Dahlström B,Hartvig P

更新日期：1982-05-01 00:00:00

abstract：:The present article should be read in conjunction with the original review published in the Journal in 1983. There is no new information of major significance about the pharmacokinetics of levonorgestrel, norethisterone (norethindrone) or ethinylestradiol, although it has been shown that the concentrations of these ho...

journal_title：Clinical pharmacokinetics

authors： Shenfield GM,Griffin JM

更新日期：1991-01-01 00:00:00

abstract：:The pharmacokinetics of oral morphine sulphate as controlled release tablets ('MS-Contin') and solution were compared at steady-state. Plasma morphine concentrations were determined over 24 hours following the last dose of each drug when given in a randomised, crossover fashion to healthy subjects. Radioimmunoassay wa...

journal_title：Clinical pharmacokinetics

authors： Savarese JJ,Goldenheim PD,Thomas GB,Kaiko RF

更新日期：1986-11-01 00:00:00

abstract：:Following administration of equivalent oral doses (30mg) of either prednisone or prednisolone to 5 patients with chronic active liver disease who had failed to respond to therapy, 5 patients with chronic active liver disease in remission induced by prednisone, and 7 healthy volunteers, corticosteroid concentrations we...

journal_title：Clinical pharmacokinetics

authors： Uribe M,Summerskill WH,Go VL

更新日期：1982-09-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:Caspofungin is an echinocandin antifungal agent used as first-line therapy for the treatment of invasive candidiasis. The maintenance dose is adapted to body weight (BW) or liver function (Child-Pugh score B or C). We aimed to study the pharmacokinetics of caspofungin and assess pharmacokineti...

journal_title：Clinical pharmacokinetics

authors： Martial LC,Brüggemann RJ,Schouten JA,van Leeuwen HJ,van Zanten AR,de Lange DW,Muilwijk EW,Verweij PE,Burger DM,Aarnoutse RE,Pickkers P,Dorlo TP

更新日期：2016-06-01 00:00:00

abstract：:Ketoprofen, a potent nonsteroidal anti-inflammatory drug (NSAID) of the 2-arylpropionic acid class, has been used clinically for over 15 years in Europe, and has recently been introduced in the United States. Although it possesses a chiral centre, with only the S-enantiomer possessing beneficial pharmacological activi...

journal_title：Clinical pharmacokinetics

authors： Jamali F,Brocks DR

更新日期：1990-09-01 00:00:00

abstract：:Physiologically-based pharmacokinetic (PBPK) modeling is a powerful tool used to characterize maturational changes in drug disposition to inform dosing across childhood; however, its use is limited in pediatric drug development. Access to pediatric pharmacokinetic data is a barrier to widespread application of this mo...

journal_title：Clinical pharmacokinetics

authors： Hornik CP,Wu H,Edginton AN,Watt K,Cohen-Wolkowiez M,Gonzalez D

更新日期：2017-11-01 00:00:00